Should I Buy ATEC? ATEC 2026 Analysis

Should You Buy Alphatec Holdings Inc (ATEC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

13.820

1 Day change

2.37%

52 Week Range

23.290

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now for a tactical rebound setup: pre-market $14.67 is sitting just above key support (S1 ~$14.50) with oversold/washed-out technicals and improving downside momentum.
Sentiment tailwinds: options positioning is bullish (puts relatively light vs calls), hedge funds are aggressively increasing buys (+316.57% QoQ), and Street targets imply meaningful upside from here.
Near-term catalyst to watch: next earnings (QDEC 2025) on 2026-02-24 (after hours)—often a volatility trigger; with you being unwilling to wait for a perfect entry, current support proximity makes this an acceptable “buy-at-support” timing.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock today.
Influential/Political flows: no recent Congress trading data available; insider activity is neutral.

Technical Analysis

Trend/Momentum: MACD histogram -0.207 (below 0) but negatively contracting → still bearish, yet selling pressure is easing (early stabilization signal).
RSI: RSI(6) ~23 → functionally oversold, supportive of a short-term bounce attempt.
Moving averages: converging MAs → trend is flattening (transition zone; often precedes a swing move).
Levels that matter now:
- Support: S1 ~$14.50 (immediate), S2 ~$13.78 (next)
- Resistance: Pivot ~$15.67 (first upside hurdle), then R1 ~$16.83
Pattern-based forward bias (provided): estimated 80% chance of gains of about +1.08% next day, +4.6% next week, +2.94% next month (supports a buy-for-bounce thesis).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Put/Call ratios (OI and volume) are low → options market skew is bullish / call-leaning.
Volatility: IV30 ~52.93 vs HV ~53.06 (roughly in-line); IV percentile ~21.6 / IV rank ~17.1 → IV is relatively low vs recent history (options not priced for extreme fear).
Activity: today’s option volume is elevated vs average (~9.68x) → increased attention/positioning into current levels.

Technical Summary

Sell

Buy

Positive Catalysts

- Operational momentum: strong top-line growth and improving gross margin (see latest quarter).

Neutral/Negative Catalysts

- Still a downtrend/weak tape technically: MACD remains below zero; failure to hold ~$14.50 can open a move toward ~$13.78.
- Profitability headwinds: net loss and EPS deterioration YoY (growth is not yet translating into earnings).
- No supportive near-term news flow: “No news in recent week” → less chance of an immediate headline-driven breakout before earnings.
- Analyst downgrade risk signal: most recent notable action included a price target cut (though rating stayed Buy).

Financial Performance

Latest quarter: 2025/Q3
Revenue: $196.5M, +30.38% YoY → strong growth.
Gross margin: 67.97%, +3.60% YoY → improving unit economics.
Net income: -$28.58M (more negative vs prior year; YoY change provided: -27.86%) → losses persist.
EPS: -0.19, down -32.14% YoY → profitability not improving yet despite revenue acceleration.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend: generally constructive with multiple raised targets into late 2025/early 2026, but TD Cowen cut PT to $20 from $27 (kept Buy) on 2026-01-26.
Latest notable calls:
- TD Cowen: Buy, PT $20 (cut from $27), sees growth vectors underappreciated.
- Barclays: Overweight, PT $27 (raised from $23).
- Freedom Capital: initiated Buy, PT $25.
- Morgan Stanley: Equal Weight, PT raised to $23 (from $21) and earlier to $21 (from $16).
Wall Street pro view (pros): above-market growth narrative, share-take potential in spine medtech, improving margins, and sizable implied upside from current price.
Wall Street con view (cons): profitability still negative and valuation/multiple assumptions can swing with comps; at least one major shop remains Equal Weight (not unanimously bullish).

12 Analyst Rating

Wall Street analysts forecast ATEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATEC is 24.55 USD with a low forecast of 19 USD and a high forecast of 28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

2 Hold

0 Sell

Strong Buy

Current: 13.500

Low

Averages

24.55

High

Current: 13.500

Low

Averages

24.55

High

TD Cowen

Buy

downgrade

$27 -> $20

AI Analysis

2026-01-26

Reason

TD Cowen

Price Target

$27 -> $20

AI Analysis

2026-01-26

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Alphatec to $20 from $27 and keeps a Buy rating on the shares following a transfer of coverage. The firm sees the company's "growth vectors" as not being fully appreciated in Street expectations. This creates potential upside to estimates, the analyst tells investors in a research note.

Barclays

Overweight

maintain

$23 -> $27

2026-01-07

Reason

Barclays

Price Target

$23 -> $27

2026-01-07

maintain

Overweight

Reason

Barclays raised the firm's price target on Alphatec to $27 from $23 and keeps an Overweight rating on the shares. The firm cites the recent increase in comparable stocks for the target multiple boost.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATEC

Unlock Now

ATEC Should I Buy

ATEC Should I Buy

Should You Buy Alphatec Holdings Inc (ATEC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch